You are here: Industry Insights > Pharma?Experts

News List

Drug-Device Combination Products: Making a Step Towards Better Adherence Suzanne Elvidge
August 01, 2025
More than half of the world’s population takes at least one medication daily, but the safety and efficacy data from clinical trials isn’t always fully reflected in real world use.
Direct-to-Consumer and Direct-to-Patient Healthcare Models Suzanne Elvidge
July 24, 2025
Accessing healthcare can be complex, and this complexity is driven by a number of different factors.
Beyond Antibiotics: The Expanding Role of Anti-Infective APIs in Bacterial Infection Suzanne Elvidge
June 13, 2025
Beyond antibiotics??, novel anti-infective approaches include ??AMPs?? targeting biofilms, ??FMT capsules?? ,nanoparticle delivery systems??, and ??synbiotics?? to combat the global ??AMR crisis??.
Radioconjugates: Targeting for Precision Suzanne Elvidge
May 06, 2025
The development of radioconjugates – targeted molecules designed to carry radionuclides directly to cancerous cells, lowering systemic exposure and increasing the precision of treatment.
Now and Next in Type 2 Diabetes Suzanne Elvidge
May 06, 2025
Type 2 diabetes, the most common form of diabetes, affects more than 800 million adults worldwide.
Oncolytic viruses in cancer treatment Suzanne Elvidge
April 21, 2025
Naturally occurring oncolytic viruses, which replicate in tumour cells and trigger apoptosis and immune responses while sparing healthy cells, were first discovered at the turn of the 19th century.
Molecular Editing in Drug Discovery: Making Peripheral and Skeletal Changes Suzanne Elvidge
April 01, 2025
Drug discovery often begins with high-throughput screening of large libraries to identify potential hits.
Falling off the Patent Cliff: Patent Expirations in 2025 and Onwards Suzanne Elvidge
March 31, 2025
In the early 2010s, a new phenomenon hit the pharmaceutical industry – the patent cliff.
Moving Forward in Translational Models Suzanne Elvidge
March 03, 2025
Translational medicine aims to bridge the gap between basic and clinical science. New translational models help predict drug efficacy and safety, but need collaboration.
Working in Rare Diseases: A Business Model Suzanne Elvidge
February 28, 2025
Rare diseases, by definition, affect a small population.